Annual Revenue Growth (Last Twelve Months): Sanofi Group (SNY)

Graphic logo of Sanofi Group (SNY)

High barriers to entry and stringent regulatory oversight provide Sanofi (SNY) with a long-term monopoly. The GURU.Markets portal illustrates the year-over-year (TTM) operating revenue trend, where the value of 23.80 corresponds to the current metric. This confirms the holding's resilience against patent risks through new developments, while the targeted hiring of mRNA experts strengthens the company's human capital potential.

SNY Sanofi Group: Sales Growth YoY (Last Twelve Months) in the range 02/11/2024 - 11/18/2026
Manufactured product of Sanofi Group

Stable revenue is critical for Sanofi (SNY) amid fierce competition in the immunology segment and patent cliff risks. This metric, reflecting the percentage change in sales over the last 12 months compared to the previous 12 months, measures the actual speed of business expansion and the effectiveness of pipeline renewal. Analyzing this trend allows investors to promptly recognize demand stagnation or the success of new drugs, assessing the company's fundamental viability.